Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID‐19) pandemic: an international accelerated consensus statementCitation formats

  • External authors:
  • Zafer Tandogdu
  • Justin Collins
  • Greg Shaw
  • Jennifer Rohn
  • Bela Koves
  • Ahmed Ghazi
  • Alexander Haese
  • Alex Mottrie
  • Anup Kumar
  • Ananthakrishnan Sivaraman
  • Ashutosh Tewari
  • Benjamin Challacombe
  • Bernardo Rocco
  • Camilo Giedelman
  • Christian Wagner
  • Craig G. Rogers
  • Declan G. Murphy
  • Dmitry Pushkar
  • Gabriel Ogaya‐Pinies
  • James Porter
  • Kulthe Ramesh Seetharam
  • Markus Graefen
  • Marcelo A. Orvieto
  • Marcio Covas Moschovas
  • Oscar Schatloff
  • Peter Wiklund
  • Rafael Coelho
  • Rair Valero
  • Theo M. Reijke
  • Thomas Ahlering
  • Travis Rogers
  • Henk G. Poel
  • Vipul Patel
  • Walter Artibani
  • Florian Wagenlehner
  • Kris Maes
  • Koon H. Rha
  • Senthil Nathan
  • Truls Erik Bjerklund Johansen
  • Peter Hawkey
  • John Kelly

Standard

Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID‐19) pandemic: an international accelerated consensus statement. / Tandogdu, Zafer; Collins, Justin; Shaw, Greg; Rohn, Jennifer; Koves, Bela; Sachdeva, Ashwin; Ghazi, Ahmed; Haese, Alexander; Mottrie, Alex; Kumar, Anup; Sivaraman, Ananthakrishnan; Tewari, Ashutosh; Challacombe, Benjamin; Rocco, Bernardo; Giedelman, Camilo; Wagner, Christian; Rogers, Craig G.; Murphy, Declan G.; Pushkar, Dmitry; Ogaya‐Pinies, Gabriel; Porter, James; Seetharam, Kulthe Ramesh; Graefen, Markus; Orvieto, Marcelo A.; Moschovas, Marcio Covas; Schatloff, Oscar; Wiklund, Peter; Coelho, Rafael; Valero, Rair; Reijke, Theo M.; Ahlering, Thomas; Rogers, Travis; Poel, Henk G.; Patel, Vipul; Artibani, Walter; Wagenlehner, Florian; Maes, Kris; Rha, Koon H.; Nathan, Senthil; Johansen, Truls Erik Bjerklund; Hawkey, Peter; Kelly, John.

In: BJU international, Vol. 127, No. 6, 10.06.2021, p. 729-741.

Research output: Contribution to journalArticlepeer-review

Harvard

Tandogdu, Z, Collins, J, Shaw, G, Rohn, J, Koves, B, Sachdeva, A, Ghazi, A, Haese, A, Mottrie, A, Kumar, A, Sivaraman, A, Tewari, A, Challacombe, B, Rocco, B, Giedelman, C, Wagner, C, Rogers, CG, Murphy, DG, Pushkar, D, Ogaya‐Pinies, G, Porter, J, Seetharam, KR, Graefen, M, Orvieto, MA, Moschovas, MC, Schatloff, O, Wiklund, P, Coelho, R, Valero, R, Reijke, TM, Ahlering, T, Rogers, T, Poel, HG, Patel, V, Artibani, W, Wagenlehner, F, Maes, K, Rha, KH, Nathan, S, Johansen, TEB, Hawkey, P & Kelly, J 2021, 'Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID‐19) pandemic: an international accelerated consensus statement', BJU international, vol. 127, no. 6, pp. 729-741. https://doi.org/10.1111/bju.15299

APA

Tandogdu, Z., Collins, J., Shaw, G., Rohn, J., Koves, B., Sachdeva, A., Ghazi, A., Haese, A., Mottrie, A., Kumar, A., Sivaraman, A., Tewari, A., Challacombe, B., Rocco, B., Giedelman, C., Wagner, C., Rogers, C. G., Murphy, D. G., Pushkar, D., ... Kelly, J. (2021). Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID‐19) pandemic: an international accelerated consensus statement. BJU international, 127(6), 729-741. https://doi.org/10.1111/bju.15299

Vancouver

Author

Tandogdu, Zafer ; Collins, Justin ; Shaw, Greg ; Rohn, Jennifer ; Koves, Bela ; Sachdeva, Ashwin ; Ghazi, Ahmed ; Haese, Alexander ; Mottrie, Alex ; Kumar, Anup ; Sivaraman, Ananthakrishnan ; Tewari, Ashutosh ; Challacombe, Benjamin ; Rocco, Bernardo ; Giedelman, Camilo ; Wagner, Christian ; Rogers, Craig G. ; Murphy, Declan G. ; Pushkar, Dmitry ; Ogaya‐Pinies, Gabriel ; Porter, James ; Seetharam, Kulthe Ramesh ; Graefen, Markus ; Orvieto, Marcelo A. ; Moschovas, Marcio Covas ; Schatloff, Oscar ; Wiklund, Peter ; Coelho, Rafael ; Valero, Rair ; Reijke, Theo M. ; Ahlering, Thomas ; Rogers, Travis ; Poel, Henk G. ; Patel, Vipul ; Artibani, Walter ; Wagenlehner, Florian ; Maes, Kris ; Rha, Koon H. ; Nathan, Senthil ; Johansen, Truls Erik Bjerklund ; Hawkey, Peter ; Kelly, John. / Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID‐19) pandemic: an international accelerated consensus statement. In: BJU international. 2021 ; Vol. 127, No. 6. pp. 729-741.

Bibtex

@article{f99102a2665c466bb3884f9a5af7fec4,
title = "Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID‐19) pandemic: an international accelerated consensus statement",
abstract = "Objective: Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of patients with prostate cancer. Beyond the immediate delay a backlog for future patients is expected. The objective of this work is to develop guidance on criteria for prioritisation of surgery and reconfiguring management pathways for patients with non-metastatic prostate cancer who opt for surgical treatment. A second aim was to identify the infection prevention and control (IPC) measures to achieve a low likelihood of coronavirus disease 2019 (COVID-19) hazard if radical prostatectomy (RP) was to be carried out during the outbreak and whilst the disease is endemic. Methods: We conducted an accelerated consensus process and systematic review of the evidence on COVID-19 and reviewed international guidance on prostate cancer. These were presented to an international prostate cancer expert panel (n = 34) through an online meeting. The consensus process underwent three rounds of survey in total. Additions to the second- and third-round surveys were formulated based on the answers and comments from the previous rounds. The Consensus opinion was defined as ≥80% agreement and this was used to reconfigure the prostate cancer pathways. Results: Evidence on the delayed management of patients with prostate cancer is scarce. There was 100% agreement that prostate cancer pathways should be reconfigured and measures developed to prevent nosocomial COVID-19 for patients treated surgically. Consensus was reached on prioritisation criteria of patients for surgery and management pathways for those who have delayed treatment. IPC measures to achieve a low likelihood of nosocomial COVID-19 were coined as {\textquoteleft}COVID-19 cold{\textquoteright} sites. Conclusion: Reconfiguring management pathways for patients with prostate cancer is recommended if significant delay (>3–6 months) in surgical management is unavoidable. The mapped pathways provide guidance for such patients. The IPC processes proposed provide a framework for providing RP within an environment with low COVID-19 risk during the outbreak or when the disease remains endemic. The broader concepts could be adapted to other indications beyond prostate cancer surgery.",
keywords = "COVID-19/epidemiology, Critical Pathways, Delphi Technique, Health Care Rationing, Humans, Infection Control, Male, Pandemics, Prostatectomy, Prostatic Neoplasms/surgery, SARS-CoV-2, Time-to-Treatment",
author = "Zafer Tandogdu and Justin Collins and Greg Shaw and Jennifer Rohn and Bela Koves and Ashwin Sachdeva and Ahmed Ghazi and Alexander Haese and Alex Mottrie and Anup Kumar and Ananthakrishnan Sivaraman and Ashutosh Tewari and Benjamin Challacombe and Bernardo Rocco and Camilo Giedelman and Christian Wagner and Rogers, {Craig G.} and Murphy, {Declan G.} and Dmitry Pushkar and Gabriel Ogaya‐Pinies and James Porter and Seetharam, {Kulthe Ramesh} and Markus Graefen and Orvieto, {Marcelo A.} and Moschovas, {Marcio Covas} and Oscar Schatloff and Peter Wiklund and Rafael Coelho and Rair Valero and Reijke, {Theo M.} and Thomas Ahlering and Travis Rogers and Poel, {Henk G.} and Vipul Patel and Walter Artibani and Florian Wagenlehner and Kris Maes and Rha, {Koon H.} and Senthil Nathan and Johansen, {Truls Erik Bjerklund} and Peter Hawkey and John Kelly",
note = "Publisher Copyright: {\textcopyright} 2020 The Authors BJU International {\textcopyright} 2020 BJU International",
year = "2021",
month = jun,
day = "10",
doi = "10.1111/bju.15299",
language = "English",
volume = "127",
pages = "729--741",
journal = "BJU international",
issn = "1464-4096",
publisher = "John Wiley & Sons Ltd",
number = "6",

}

RIS

TY - JOUR

T1 - Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID‐19) pandemic: an international accelerated consensus statement

AU - Tandogdu, Zafer

AU - Collins, Justin

AU - Shaw, Greg

AU - Rohn, Jennifer

AU - Koves, Bela

AU - Sachdeva, Ashwin

AU - Ghazi, Ahmed

AU - Haese, Alexander

AU - Mottrie, Alex

AU - Kumar, Anup

AU - Sivaraman, Ananthakrishnan

AU - Tewari, Ashutosh

AU - Challacombe, Benjamin

AU - Rocco, Bernardo

AU - Giedelman, Camilo

AU - Wagner, Christian

AU - Rogers, Craig G.

AU - Murphy, Declan G.

AU - Pushkar, Dmitry

AU - Ogaya‐Pinies, Gabriel

AU - Porter, James

AU - Seetharam, Kulthe Ramesh

AU - Graefen, Markus

AU - Orvieto, Marcelo A.

AU - Moschovas, Marcio Covas

AU - Schatloff, Oscar

AU - Wiklund, Peter

AU - Coelho, Rafael

AU - Valero, Rair

AU - Reijke, Theo M.

AU - Ahlering, Thomas

AU - Rogers, Travis

AU - Poel, Henk G.

AU - Patel, Vipul

AU - Artibani, Walter

AU - Wagenlehner, Florian

AU - Maes, Kris

AU - Rha, Koon H.

AU - Nathan, Senthil

AU - Johansen, Truls Erik Bjerklund

AU - Hawkey, Peter

AU - Kelly, John

N1 - Publisher Copyright: © 2020 The Authors BJU International © 2020 BJU International

PY - 2021/6/10

Y1 - 2021/6/10

N2 - Objective: Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of patients with prostate cancer. Beyond the immediate delay a backlog for future patients is expected. The objective of this work is to develop guidance on criteria for prioritisation of surgery and reconfiguring management pathways for patients with non-metastatic prostate cancer who opt for surgical treatment. A second aim was to identify the infection prevention and control (IPC) measures to achieve a low likelihood of coronavirus disease 2019 (COVID-19) hazard if radical prostatectomy (RP) was to be carried out during the outbreak and whilst the disease is endemic. Methods: We conducted an accelerated consensus process and systematic review of the evidence on COVID-19 and reviewed international guidance on prostate cancer. These were presented to an international prostate cancer expert panel (n = 34) through an online meeting. The consensus process underwent three rounds of survey in total. Additions to the second- and third-round surveys were formulated based on the answers and comments from the previous rounds. The Consensus opinion was defined as ≥80% agreement and this was used to reconfigure the prostate cancer pathways. Results: Evidence on the delayed management of patients with prostate cancer is scarce. There was 100% agreement that prostate cancer pathways should be reconfigured and measures developed to prevent nosocomial COVID-19 for patients treated surgically. Consensus was reached on prioritisation criteria of patients for surgery and management pathways for those who have delayed treatment. IPC measures to achieve a low likelihood of nosocomial COVID-19 were coined as ‘COVID-19 cold’ sites. Conclusion: Reconfiguring management pathways for patients with prostate cancer is recommended if significant delay (>3–6 months) in surgical management is unavoidable. The mapped pathways provide guidance for such patients. The IPC processes proposed provide a framework for providing RP within an environment with low COVID-19 risk during the outbreak or when the disease remains endemic. The broader concepts could be adapted to other indications beyond prostate cancer surgery.

AB - Objective: Coronavirus disease-19 (COVID-19) pandemic caused delays in definitive treatment of patients with prostate cancer. Beyond the immediate delay a backlog for future patients is expected. The objective of this work is to develop guidance on criteria for prioritisation of surgery and reconfiguring management pathways for patients with non-metastatic prostate cancer who opt for surgical treatment. A second aim was to identify the infection prevention and control (IPC) measures to achieve a low likelihood of coronavirus disease 2019 (COVID-19) hazard if radical prostatectomy (RP) was to be carried out during the outbreak and whilst the disease is endemic. Methods: We conducted an accelerated consensus process and systematic review of the evidence on COVID-19 and reviewed international guidance on prostate cancer. These were presented to an international prostate cancer expert panel (n = 34) through an online meeting. The consensus process underwent three rounds of survey in total. Additions to the second- and third-round surveys were formulated based on the answers and comments from the previous rounds. The Consensus opinion was defined as ≥80% agreement and this was used to reconfigure the prostate cancer pathways. Results: Evidence on the delayed management of patients with prostate cancer is scarce. There was 100% agreement that prostate cancer pathways should be reconfigured and measures developed to prevent nosocomial COVID-19 for patients treated surgically. Consensus was reached on prioritisation criteria of patients for surgery and management pathways for those who have delayed treatment. IPC measures to achieve a low likelihood of nosocomial COVID-19 were coined as ‘COVID-19 cold’ sites. Conclusion: Reconfiguring management pathways for patients with prostate cancer is recommended if significant delay (>3–6 months) in surgical management is unavoidable. The mapped pathways provide guidance for such patients. The IPC processes proposed provide a framework for providing RP within an environment with low COVID-19 risk during the outbreak or when the disease remains endemic. The broader concepts could be adapted to other indications beyond prostate cancer surgery.

KW - COVID-19/epidemiology

KW - Critical Pathways

KW - Delphi Technique

KW - Health Care Rationing

KW - Humans

KW - Infection Control

KW - Male

KW - Pandemics

KW - Prostatectomy

KW - Prostatic Neoplasms/surgery

KW - SARS-CoV-2

KW - Time-to-Treatment

U2 - 10.1111/bju.15299

DO - 10.1111/bju.15299

M3 - Article

C2 - 33185026

VL - 127

SP - 729

EP - 741

JO - BJU international

JF - BJU international

SN - 1464-4096

IS - 6

ER -